Severe Hypertriglyceridemia Associated with Pegylated Asparaginase Successfully Treated with Plasma Exchange. (August 2022)

• Record Type: Journal Article
• Authors: Cuevas, Rafael-Emmanuel; Cid, Joan; Carbonell-Ordeig, Sara; Álvarez-Larran, Alberto; Lozano, Miquel
• Is Part Of: Plasmatology. Volume 16(2022)
• Publication Date: 2022-08
• Subjects: Pegylated asparaginase -- hypertriglyceridemia -- plasma exchange -- apheresis; Blood plasma -- Periodicals; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 612.116
• DOI: 10.1177/26348535221107531
• Languages: English
• ISSNs: 2634-8535

Abstract

Asparaginase (ASP), a chemotherapy treatment used for acute lymphoblastic leukemia (ALL), is known to provoke severe hypertriglyceridemia (HTG). We report the case of a woman with a history of obesity and diabetes mellitus who developed severe HTG (up to 7305 mg/dL) after receiving a pegylated form of ASP for ALL. The patient was treated with one plasma exchange without incident via peripheral veins using 5% albumin as a replacement solution. Her triglycerides were reduced to 485 mg/dL. A single plasma exchange was an efficient, fast, and safe way to decrease triglycerides concentration in plasma.